The history of neuromyelitis optica, Journal of Neuroinflammation, issue.1, p.10, 2013. ,
Structure and function of aquaporin water channels, American Journal of Physiology-Renal Physiology, vol.278, issue.1, pp.13-28, 2000. ,
More than just water channels: unexpected cellular roles of aquaporins, Journal of Cell Science, vol.118, issue.15, pp.3225-3232, 2005. ,
Specialized Membrane Domains for Water Transport in Glial Cells: High-Resolution Immunogold Cytochemistry of Aquaporin-4 in Rat Brain, The Journal of Neuroscience, vol.17, issue.1, pp.171-180, 1997. ,
Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder, Neuropathology and Applied Neurobiology, vol.46, issue.3, pp.199-218, 2019. ,
Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema, The FASEB Journal, vol.18, issue.11, pp.1291-1293, 2004. ,
, Biology of AQP4 and Anti
Therapeutic Implications for NMO, Brain Pathology, vol.23, issue.6, pp.684-695, 2013. ,
Involvement of aquaporin-4 in astroglial cell migration and glial scar formation, Journal of Cell Science, vol.118, issue.24, pp.5691-5698, 2005. ,
Increased seizure duration and slowed potassium kinetics in mice lacking aquaporin-4 water channels, Glia, vol.53, issue.6, pp.631-636, 2006. ,
Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation, The FASEB Journal, vol.25, issue.5, pp.1556-1566, 2011. ,
Aquaporins in Brain: Distribution, Physiology, and Pathophysiology, Journal of Cerebral Blood Flow & Metabolism, vol.22, issue.4, pp.367-378, 2002. ,
,
, Identification of Two Major Conformational Aquaporin-4 Epitopes for Neuromyelitis Optica Autoantibody Binding, Journal of Biological Chemistry, vol.286, issue.11, pp.9216-9224, 2011.
Aquaporin 4 Expression and Tissue Susceptibility to Neuromyelitis Optica, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD 13, vol.70, p.1118, 2013. ,
Role of membrane complement regulators in neuromyelitis optica, Multiple Sclerosis Journal, vol.21, issue.13, pp.1644-1654, 2015. ,
Augmentation of ,
,
, Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex, Proceedings of the National Academy of Sciences, vol.90, issue.17, pp.7990-7994, 1993.
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders, Journal of Neuroinflammation, vol.8, issue.1, p.184, 2011. ,
Complex alternative splicing of the myelin oligodendrocyte glycoprotein gene is unique to human and non-human primates, Journal of Neurochemistry, vol.98, issue.6, pp.1707-1717, 2006. ,
URL : https://hal.archives-ouvertes.fr/hal-00091116
Myelin oligodendrocyte glycoprotein antibodies in neurological disease, Nature Reviews Neurology, vol.15, issue.2, pp.89-102, 2018. ,
The Structure and Function of Myelin Oligodendrocyte Glycoprotein, Journal of Neurochemistry, vol.72, issue.1, pp.1-9, 1999. ,
Sex differences in autoimmune disorders of the central nervous system, Seminars in Immunopathology, vol.41, issue.2, pp.177-188, 2018. ,
Worldwide prevalence of neuromyelitis optica spectrum disorders, Neurosurgery & Psychiatry, vol.89, issue.6, pp.555-556, 2018. ,
A population-based study of neuromyelitis optica in Caucasians, Neurology, vol.76, issue.18, pp.1589-1595, 2011. ,
,
, Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum, Annals of Neurology, vol.79, issue.5, pp.775-783, 2016.
,
, Neuromyelitis Optica in the World: A Systematic Review and Meta-Analysis. Multiple Sclerosis International, vol.2015, pp.1-8, 2015.
Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD 26 ,
, Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance, Journal of Neuroinflammation, vol.7, issue.1, p.52, 2010.
Glucoseregulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica, Science Translational Medicine, vol.9, issue.397, p.9111, 2017. ,
Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat, Acta Neuropathol (Berl), vol.137, 2018. ,
Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6, Multiple Sclerosis Journal, vol.16, issue.12, pp.1443-1452, 2010. ,
,
, Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis, PLoS ONE, vol.8, issue.4, p.61835, 2013.
IL-6: Regulator of Treg/Th17 balance, European Journal of Immunology, vol.40, issue.7, pp.1830-1835, 2010. ,
Th17 cells in neuromyelitis optica spectrum disorder: a review, International Journal of Neuroscience, vol.126, issue.12, pp.1051-1060, 2016. ,
Interleukin 6 of the National Academy of Sciences, vol.108, pp.3701-3706, 2011. ,
,
, Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss, Acta Neuropathologica, vol.123, issue.6, pp.861-872, 2012.
,
, Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter, Annals of Neurology, vol.72, issue.1, pp.53-64, 2012.
Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens, Annals of Neurology, vol.80, issue.3, pp.443-447, 2016. ,
, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2, Journal of Experimental Medicine, vol.205, issue.11, pp.2473-2481, 2008. ,
Aquaporin-4 deficiency down-regulates glutamate uptake and GLT-1 expression in astrocytes, Molecular and Cellular Neuroscience, vol.34, issue.1, pp.34-39, 2007. ,
Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica, Neurology, vol.69, issue.24, pp.2221-2231, 2007. ,
Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes, Proceedings of the National Academy of Sciences, vol.109, issue.4, pp.1245-1250, 2011. ,
Neuromyelitis optica: Aquaporin-4 based pathogenesis mechanisms and new therapies, The International Journal of Biochemistry & Cell Biology, vol.44, issue.9, pp.1519-1530, 2012. ,
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica, Brain, vol.131, issue.11, pp.3072-3080, 2008. ,
Neuromyelitis optica: a positive appraisal of seronegative cases, European Journal of Neurology, vol.22, issue.12, pp.1511-83, 2015. ,
,
, Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity, Neurology, vol.80, issue.24, pp.2194-2200, 2013.
, , p.4
, IgG serostatus and disability outcome in neuromyelitis optica, Neurology, vol.81, issue.14, pp.1197-1204, 2013.
The clinical course of neuromyelitis optica (Devic's syndrome), Neurology, vol.53, issue.5, pp.1107-1107, 1999. ,
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis, The Lancet, vol.364, issue.9451, pp.2106-2112, 2004. ,
Evaluation of aquaporin-4 antibody assays, Clinical and Experimental Neuroimmunology, vol.5, issue.3, pp.290-303, 2014. ,
, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD
Revised diagnostic criteria for neuromyelitis optica, Neurology, vol.66, issue.10, pp.1485-1489, 2006. ,
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders, Neurology, vol.85, issue.2, pp.177-189, 2015. ,
The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates, Multiple Sclerosis Journal, vol.23, issue.2, pp.228-233, 2016. ,
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin, Journal of Neuroinflammation, vol.13, issue.1, 2016. ,
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome, Journal of Neuroinflammation, vol.13, issue.1, 2016. ,
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement -frequency, presentation and outcome, Journal of Neuroinflammation, vol.13, issue.1, 2016. ,
,
Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgGseropositive patients, NMO and related disorders: a multicenter study of 50 patients, vol.4, 2016. ,
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders, Neurology, vol.83, issue.5, pp.475-476, 2014. ,
What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients, Journal of Neurology, vol.264, issue.10, pp.2088-2094, 2017. ,
Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype, Journal of Neuroinflammation, vol.12, issue.1, 2015. ,
Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD 59, vol.5, pp.7766-007766, 2015. ,
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD, Science China Life Sciences, vol.59, issue.12, pp.1270-1281, 2016. ,
Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease, JAMA Neurology, vol.75, issue.1, p.65, 2018. ,
,
, Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease, Multiple Sclerosis Journal, vol.21, issue.7, pp.866-874, 2014.
Etiologies of acute demyelinating optic neuritis: an observational study of 110 patients, European Journal of Neurology, vol.24, issue.6, pp.875-879, 2017. ,
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis, Journal of Neuroimmunology, vol.275, issue.1-2, pp.23-24, 2014. ,
Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study, Neurology, vol.90, issue.21, pp.1858-1869, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01919569
Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France, Journal of Neurology, vol.264, issue.10, pp.2173-2175, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01745944
,
, Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome, American Journal of Ophthalmology, vol.195, pp.8-15, 2018.
,
, Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis, Neurology -Neuroimmunology Neuroinflammation, vol.2, issue.4, p.131, 2015.
Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes, Revue Neurologique, vol.174, issue.6, pp.458-470, 2018. ,
Neurological update: MOG antibody disease, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD 70, vol.266, pp.1280-1286, 2018. ,
Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions, Acta Neuropathologica, vol.75, issue.6, pp.566-576, 1988. ,
MHC Class II-Regulated Central Nervous System Autoaggression and T Cell Responses in Peripheral Lymphoid Tissues Are Dissociated in Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis, The Journal of Immunology, vol.166, issue.12, pp.7588-7599, 2001. ,
Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibodyassociated syndromes: a multicenter study, Journal of Neurology, vol.264, issue.12, pp.2420-2430, 2017. ,
Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG-and MOG-IgG-associated diseases, Current Opinion in Neurology, vol.33, issue.3, pp.362-371, 2020. ,
Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination, Journal of Neuroinflammation, vol.14, issue.1, 2017. ,
The myelin oligodendrocyte glycoprotein directly binds nerve growth factor to modulate central axon circuitry, Journal of Cell Biology, vol.210, issue.6, pp.891-898, 2015. ,
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain, Acta Neuropathologica Communications, vol.2, issue.1, 2014. ,
,
, T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease, Proceedings of the National Academy of Sciences, vol.113, issue.12, pp.3323-3328, 2016.
,
, Histopathology and clinical course of MOG-antibody-associated encephalomyelitis, Annals of Clinical and Translational Neurology, vol.2, issue.3, pp.295-301, 2015.
Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD, Neurology, vol.87, issue.2, pp.229-231, 2016. ,
Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies, Neurosurgery & Psychiatry, vol.87, issue.11, pp.1257-1259, 2016. ,
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing, Journal of Neuroinflammation, vol.15, issue.1, 2018. ,
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations, Practical Neurology, vol.19, issue.3, pp.187-195, 2018. ,
, Clinical Spectrum and Treatment
, Neuromyelitis Optica Spectrum Disorders: Evolution and Current Status, Brain Pathology, vol.23, issue.6, pp.647-660, 2013.
Painful Tonic Spasm in Neuromyelitis Optica, Archives of Neurology, vol.69, issue.8, 2012. ,
,
, Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients, Journal of Neuroinflammation, vol.9, issue.1, 2012.
Circumventricular organs: Receptive and homeostatic functions and clinical implications, Neurology, vol.77, issue.12, pp.1198-1204, 2011. ,
Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations, Neurosurgery & Psychiatry, vol.79, issue.9, pp.1075-1078, 2008. ,
Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients, Multiple Sclerosis Journal, vol.20, issue.7, pp.843-847, 2013. ,
Neuromyelitis Optica Spectrum Disorders: Spectrum of MR Imaging Findings and Their Differential Diagnosis, RadioGraphics, vol.38, issue.1, pp.169-193, 2018. ,
Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody, JAMA Neurology, vol.76, issue.3, p.301, 2019. ,
Myelitis with normal spinal cord MRI: don't forget anti-MOG antibodies disease!, Acta Neurologica Belgica, 2020. ,
,
, Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies, Multiple Sclerosis Journal, p.135245852090790, 2020.
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis ,
, Brain J Neurol, vol.120, pp.2059-69, 1997.
Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange, Multiple Sclerosis Journal, vol.22, issue.2, pp.185-192, 2015. ,
Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses, Annals of Neurology, vol.79, issue.2, pp.206-216, 2015. ,
,
, A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease, Annals of Neurology, vol.46, issue.6, pp.878-886, 1999.
Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder, Multiple Sclerosis Journal, vol.15, issue.4, pp.487-492, 2009. ,
Plasma exchange in neurological disease ,
, Practical Neurology, vol.20, issue.2, pp.92-99, 2019.
, Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for
, Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders. Case Medical Research, ClinicalTrials.gov, 2019.
Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders, Neurosurgery & Psychiatry, vol.89, issue.4, pp.346-351, 2017. ,
Plasma Exchange in Severe Attacks of Neuromyelitis Optica ,
, Multiple Sclerosis International, vol.2012, pp.1-9, 2012.
, Evidence-based guideline update: Plasmapheresis in neurologic disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, vol.76, pp.294-300, 2011.
, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD
,
, Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue, Journal of Clinical Apheresis, vol.31, issue.3, pp.149-338, 2016.
Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients, Multiple Sclerosis Journal, vol.20, issue.4, pp.501-504, 2013. ,
Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica, Neurology -Neuroimmunology Neuroinflammation, vol.1, issue.1, p.5, 2014. ,
Treatment of neuromyelitis optica: Review and recommendations. Multiple Sclerosis and Related Disorders, vol.1, pp.180-187, 2012. ,
,
, Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response, Neurosurgery & Psychiatry, vol.88, issue.8, pp.639-647, 2017.
Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis, Multiple Sclerosis Journal, vol.13, issue.8, pp.968-974, 2007. ,
Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination, Neurosurgery & Psychiatry, vol.89, issue.2, pp.127-137, 2017. ,
Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica, Journal of Neuroimmunology, vol.282, pp.92-96, 2015. ,
,
, Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica, Neurology, vol.77, issue.7, pp.659-666, 2011.
Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial, Journal of Neurology, vol.264, issue.9, pp.2003-2009, 2017. ,
Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease, Journal of Neuroinflammation, vol.16, issue.1, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02180590
, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD
Treatment of Neuromyelitis Optica With Mycophenolate Mofetil: retrospective analysis of 24 patients, Archives of Neurology, vol.66, issue.9, 2009. ,
, The Efficacy and Tolerability
, Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China, Clinical Neuropharmacology, vol.39, issue.2, pp.81-87, 2016.
Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder, Journal of the Neurological Sciences, vol.385, pp.192-197, 2018. ,
Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder, European Journal of Neurology, vol.24, issue.1, pp.219-226, 2016. ,
Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders, Multiple Sclerosis Journal, vol.23, issue.10, pp.1377-1384, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01798528
, Aquaporin-4 Sclerosis Journal, vol.24, issue.13, pp.1737-1742, 2017.
An open label study of the effects of rituximab in neuromyelitis optica, Neurology, vol.64, issue.7, pp.1270-1272, 2005. ,
Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: multicenter study of treatment efficacy, JAMA Neurology, vol.71, issue.3, p.324, 2014. ,
,
, Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability, Journal of Neurology, vol.262, issue.10, pp.2329-2335, 2015.
Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study, Journal of Neurology, vol.265, issue.4, pp.917-925, 2018. ,
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate, BMC Neurology, vol.14, issue.1, 2014. ,
, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD
Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 ,
, Neurosurgery & Psychiatry, vol.84, issue.8, pp.918-921, 2013.
,
, Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment. Multiple Sclerosis and Related Disorders, vol.7, pp.21-25, 2016.
Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study, Neurosurgery & Psychiatry, vol.84, issue.5, pp.511-516, 2012. ,
Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study, Neurology, vol.82, issue.15, pp.1302-1306, 2014. ,
Longterm Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder, JAMA Neurology, vol.72, issue.7, p.756, 2015. ,
, Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
,
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. The Lancet, vol.394, pp.1352-1363, 2019. ,
,
, Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an openlabel pilot study. The Lancet Neurology, vol.12, pp.554-562, 2013.
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder, New England Journal of Medicine, vol.381, issue.7, pp.614-625, 2019. ,
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder, New England Journal of Medicine, vol.381, issue.22, pp.2114-2124, 2019. ,
,
, Efficacy and safety of satralizumab monotherapy for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD): Results from SAkuraStar, a double-blind placebo-controlled phase 3 clinical study, Journal of the Neurological Sciences, vol.405, p.171, 2019.
Efficacy of satralizumab as monotherapy in pre-specified subgroups of SAkuraStar, a doubleblind placebo-controlled phase 3 clinical study in patients with neuromyelitis optica spectrum disorder (NMOSD), Journal of the Neurological Sciences, vol.405, p.172, 2019. ,
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options, Drugs, vol.79, issue.2, pp.125-142, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02554078
Natural History of the Visual Impairment of Relapsing Neuromyelitis Optica, Ophthalmology, vol.114, issue.4, p.810, 2007. ,
Relapsing neuromyelitis optica: long term history and clinical predictors of death, Neurosurgery & Psychiatry, vol.80, issue.10, pp.1162-1164, 2009. ,
Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica, Multiple Sclerosis Journal, vol.13, issue.1, pp.128-132, 2007. ,
Apheresis therapies for NMOSD attacks, Neurology -Neuroimmunology Neuroinflammation ,
Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis, Neurology -Neuroimmunology Neuroinflammation, 2019. ,
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-1444, 1983. ,
, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD